Key result
LAAC cuts hemorrhagic stroke ~66% vs. warfarin with equivalent ischemic stroke protection.
Why the study?
Left atrial appendage closure and direct oral anticoagulants have emerged as alternatives to warfarin for stroke prevention in atrial fibrillation, but recent trials have shown variable results.
Do left atrial appendage closure (LAAC) and direct oral anticoagulants (DOACs) reduce ischemic stroke, systemic embolism, and hemorrhagic stroke compared with warfarin in patients with non-valvular atrial fibrillation?
Meta-Analysis (n=78,594)
Device-based trials were open-label by necessity; pharmacological trials employed double-blind designs where feasible.
Yes
Do left atrial appendage closure (LAAC) and direct oral anticoagulants (DOACs) reduce ischemic stroke, systemic embolism, and hemorrhagic stroke compared with warfarin in patients with non-valvular atrial fibrillation?
In over 78,000 patients across 10 RCTs, both LAAC and DOACs provided equivalent ischemic stroke protection to warfarin while significantly reducing hemorrhagic stroke and net adverse clinical events, supporting LAAC as a viable non-pharmacological alternative to oral anticoagulation in selected AF patients.
Answers are grounded in this paper and cite their sources.
Supports preferring LAAC or DOACs over warfarin to reduce hemorrhagic stroke in AF; confirms and extends prior RCTs via network meta-analysis.
Background Left atrial appendage closure (LAAC) and direct oral anticoagulants (DOACs) have emerged as alternatives to warfarin for stroke prevention in atrial fibrillation (AF). However, recent trials have shown variable results igniting the debate on this topic. Methods We performed a systematic review and network meta-analysis (NMA) of RCTs comparing LAAC, DOACs, and warfarin in patients with AF. The primary efficacy outcome was ischemic stroke or systemic embolism (IS/SE) and the primary bleeding outcome was hemorrhagic stroke (HS). Secondary outcomes included net adverse clinical events (NACE) and major or clinically relevant bleeding (MCRB). Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using a random-effects model. Results Ten RCTs (LAAC: 6 trials; DOAC: 8 trials; warfarin: 6 trials) enrolling 78,594 patients fulfilled the inclusion criteria. There were no significant differences for the primary efficacy outcome of IS/SE among the 3 strategies. However, when compared with warfarin, both DOACs (OR 0·43, 95% CI 0·34–0·54) and LAAC (OR 0·34, 95% CI 0·18–0·63) reduced the primary safety outcome of HS, with no significant difference between them (OR 0·79, 95% CI 0·44–1·3). For NACE, both DOACs (OR 0·87, 95% CI 0·83–0·91) and LAAC (OR 0·85, 95% CI 0·73–0·99) were superior to warfarin, with similar performance between them (OR 0·98, 95% CI 0·84–1·13). For MCRB, DOACs were superior to warfarin (OR 0·79, 95% CI 0·63–0·99), while LAAC showed a non-significant trend towards benefit. Conclusion In this meta-analysis of RCTs with data from over 78,000 patients, LAAC and DOACs significantly reduced NACE driven by lower hemorrhagic stroke and provided equivalent IS/SE protection compared with warfarin, making LAAC a potential viable alternative to oral anticoagulation in appropriately selected AF patients.
No takes yet. Share an insight, caveat, or question.
Pancholy et al. (2026) conducted a meta-analysis in Atrial fibrillation (n=78,594). Left atrial appendage closure (LAAC) and direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Hemorrhagic stroke (primary safety outcome; primary efficacy outcome of ischemic stroke or systemic embolism showed no significant difference) (OR 0.34, 95% CI 0.18-0.63). LAAC (OR 0.34, 95% CI 0.18-0.63) and DOACs (OR 0.43, 95% CI 0.34-0.54) significantly reduced hemorrhagic stroke with equivalent ischemic stroke protection compared with warfarin.
Synapse has enriched 10 related papers. Consider them for comparative context: